Peer-reviewed veterinary case report
New antibody treatment tested for advanced cancer in dogs
By M. Igase et al.·Published in Scientific Reports·2020·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
- Species:
- dog
Plain-English summary
A group of dogs with advanced oral malignant melanoma, a serious type of cancer, was treated with a new therapeutic antibody designed to boost their immune response. This treatment aimed to help the dogs fight their cancer more effectively. The study found that the antibody was relatively safe and showed promising results in improving the dogs' condition. This suggests that using this type of treatment could be a valuable option for dogs suffering from aggressive cancers.
People also search for: dog melanoma treatment · advanced cancer in dogs · immune therapy for dogs · canine cancer antibody treatment
Abstract
Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for the advanced stages of melanoma in veterinary medicine. Only one previous study indicated the potential of the immune checkpoint inhibitor, anti-canine PD-L1 therapeutic antibody in dogs, and no anti-canine PD-1 therapeutic antibodies are currently available. Here, we developed two therapeutic antibodies, rat-dog chimeric and caninized anti-canine PD-1 monoclonal antibodies and evaluated in vitro functionality for these antibodies. Moreover, we conducted a pilot study to determine their safety profiles and clinical efficacy in spontaneously occurring canine cancers. In conclusion, the anti-canine PD-1 monoclonal antibody was relatively safe and effective in dogs with advanced oral malignant melanoma and other cancers. Thus, our study suggests that PD-1 blockade may be an attractive treatment option in canine cancers.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/33110170